Pfizer Expands Generics Portfolio with India Deals

Pfizer has entered into licensing agreements with two pharmaceutical companies based in India, boosting its position in emerging markets and significantly expanding its portfolio of medicines in its Established Products Business Unit.

The company has expanded its pact with Aurobindo Pharma Ltd., acquiring rights to 55 solid oral dose products and 5 sterile injectable products for patients in more than 70 emerging market countries. “This deal illustrates the types of innovative partnerships which will help to advance Pfizer’s presence in developing markets and enhance access to needed medicines for billions worldwide,” said Jean-Michel Halfon, president and general manager of Pfizer’s Emerging Markets Business Unit. “The expansion of our product portfolio from this deal provides a foundation for us to commercialize branded generics based on patient needs within specific regions.”

The acquisition includes antibiotics and anti-infectives, and covers a broad range of disease areas like cardiovascular and central nervous system disorders. Pfizer will commercialize the 60 products in phases tailoring its approach for different regions. Pfizer also expanded agreements with Aurobindo in developed markets, adding products in the U.S. and Europe. Financial terms of the deal were not disclosed.

Pfizer has also entered into agreements with Claris Lifesciences Ltd. to commercialize sterile injectable medicines after the products are no longer patent protected, and have lost market exclusivity in North America, Europe, Australia and New Zealand. The Claris agreements advance Pfizer’s Established Products strategy, which focuses on the commercialization of products where market exclusivity has been lost. Pfizer’s global annual sales of established products are approximately $10 billion.

As part of the deal, Pfizer has acquired rights to 15 injectable products covering a broad range of therapeutic areas including anti-infectives and pain. Financial terms were not disclosed.

“These agreements advance our goals to expand our steriles portfolio and provide hospitals and patients with a wide offering of affordable medicines they can trust. Pfizer’s reputation for high quality and supply reliability is unrivaled in the industry, and this is critical in the area of sterile injectables,” said David Simmons, president and general manager of Pfizer’s Established Products Business Unit.

To date, 128 non-Pfizer products – 98 solid oral dose and 30 sterile injectables – have been added to the Company’s existing diversified portfolio of established brands.